^
Association details:
| Biomarker: | EGFR-SEPTIN14 fusion + EGFR amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib
Excerpt:
Here we describe a case of a 63-year-old man...Then the patient received a nine-cycle combination treatment of XELOX and bevacizumab and showed progressive disease (PD)….Paraffin sections of postoperative colorectal tissue were subjected to next-generation sequencing, and epidermal growth factor receptor (EGFR) amplification and rare EGFR-SEPT14 fusion were identified.
Secondary therapy:
CAPOX
DOI:
10.1634/theoncologist.2019-0405
